Perspective Therapeutics to Participate at Upcoming Investor Conferences
26 Februar 2024 - 2:00PM
Perspective Therapeutics, Inc. (“Perspective” or “the
Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that
is pioneering advanced treatment applications for cancers
throughout the body, today announced that management will
participate at upcoming discussions and investor conferences in
February and March, 2024.
- Fireside Chat with
JonesResearch – February 28, virtualTime: 11 a.m.
ETParticipant: Michael K. Schultz, Ph.D., Chief Science
OfficerPlease RSVP to your JonesResearch representative. Additional
details will be provided upon registration.
- B. Riley Securities Inaugural Radiopharma Day – March
1, New York, NYPanel: The Year Pb212 to Shine: What It
Takes To Have A Robust Supply of Pb212-based
Radiopharmaceuticals?Time: 10 a.m. ETParticipant: Thijs Spoor,
Chief Executive OfficerPanel: Good But Not The Best Yet: Drug
Designs to Beat Standard of CareTime: 1:45 p.m. ETParticipant:
Markus Puhlman, MD, Chief Medical OfficerPanel: Enough with Lu177
and Ac225? Other Isotopes in Store for RadiopharmaTime: 2:30 p.m.
ETParticipant: Amos Hedt, Chief Business Strategy OfficerPlease
RSVP to your B. Riley Securities representative, additional details
will be provided upon registration.
About Perspective Therapeutics, Inc.Perspective
Therapeutics, Inc., is a radiopharmaceutical development company
that is pioneering advanced treatment applications for cancers
throughout the body. The Company has a proprietary technology that
utilizes the alpha emitting isotope 212Pb to deliver powerful
radiation specifically to cancer cells via specialized targeting
peptides. The Company is also developing complementary imaging
diagnostics that incorporate the same targeting peptides which
provide the opportunity to personalize treatment and optimize
patient outcomes. This "theranostic" approach enables the ability
to see the specific tumor and then treat it to potentially improve
efficacy and minimize toxicity associated with many other types of
cancer treatments.
The Company's melanoma (VMT01) and neuroendocrine tumor
(VMT-α-NET) programs have entered Phase 1/2a imaging and therapy
trials for the treatment of metastatic melanoma and neuroendocrine
tumors at several leading academic institutions. The Company has
also developed a proprietary 212Pb generator to secure key isotopes
for clinical trial and commercial operations.
For more information, please visit the Company's website at
www.perspectivetherapeutics.com.
Safe Harbor StatementThis press release
contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995.
Statements in this press release that are not statements of
historical fact are forward-looking statements. Words such as
“may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”
“intend,” “target,” “project,” “estimate,” “believe,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions are intended to identify forward-looking
statements, though not all forward-looking statements contain these
identifying words. Forward-looking statements in this press release
include statements concerning, among other things: the Company’s
prediction that complementary imaging diagnostics that incorporate
certain targeting peptides provide the opportunity to personalize
treatment and optimize patient outcomes; the Company’s expectation
that its “theranostic” approach enables the ability to see specific
tumors and then treat them to potentially improve efficacy and
minimize toxicity associated with many other types of cancer
treatments; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or
expectations disclosed in the forward-looking statements and you
should not place undue reliance on the forward-looking statements.
These forward-looking statements involve risks and uncertainties
that could cause the Company’s actual results to differ materially
from the results described in or implied by the forward-looking
statements, including, without limitation: the Company’s ability to
continue as a going concern; the potential that regulatory
authorities may not grant or may delay approval for the Company’s
product candidates; uncertainties and delays relating to the
design, enrollment, completion, and results of clinical trials;
unanticipated costs and expenses; early clinical trials may not be
indicative of the results in later clinical trials; clinical trial
results may not support regulatory approval or further development
in a specified indication or at all; actions or advice of
regulatory authorities may affect the design, initiation, timing,
continuation and/or progress of clinical trials or result in the
need for additional clinical trials; the Company’s ability to
obtain and maintain regulatory approval for the Company’s product
candidates; delays, interruptions or failures in the manufacture
and supply of the Company’s product candidates; the size and growth
potential of the markets for the Company’s product candidates, and
the Company’s ability to service those markets; the Company’s cash
and cash equivalents may not be sufficient to support its operating
plan for as long as anticipated; the Company’s expectations,
projections and estimates regarding expenses, future revenue,
capital requirements, and the availability of and the need for
additional financing; the Company’s ability to obtain additional
funding to support its clinical development programs; the
availability or potential availability of alternative products or
treatments for conditions targeted by the Company that could affect
the availability or commercial potential of its product candidates;
the ability of the Company to manage growth and successfully
integrate its businesses; the Company’s ability to maintain its key
employees; whether there is sufficient training and use of the
Company’s products and product candidates; the market acceptance
and recognition of the Company’s products and product candidates;
the Company’s ability to maintain and enforce its intellectual
property rights; the Company’s ability to maintain its therapeutic
isotope supply agreement with the Department of Energy; the
Company’s ability to continue to comply with the procedures and
regulatory requirements mandated by the FDA for additional trials,
Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval
and reimbursement codes; and any changes in applicable laws and
regulations. Other factors that may cause the Company’s actual
results to differ materially from those expressed or implied in the
forward-looking statements in this press release are described
under the heading “Risk Factors” in the Company’s most recent
Transition Report on Form 10-KT and the Company’s most recent
Quarterly Report on Form 10-Q, each filed with the Securities and
Exchange Commission (the “SEC”), in the Company’s other filings
with the SEC, and in the Company’s future reports to be filed with
the SEC and available at www.sec.gov.
Forward-looking statements contained in this
press release are made as of this date, and the Company undertakes
no duty to update such information whether as a result of new
information, future events or otherwise, except as required under
applicable law.
Media and Investor Relations Contacts:
Russo Partners, LLC
Nic Johnson
nic.johnson@russopartnersllc.com
Adanna G. Alexander, Ph.D.
adanna.alexander@russopartnersllc.com
Harrison Seidner, Ph.D.
harrison.seidner@russopartnersllc.com
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Perspective Therapeutics (AMEX:CATX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024